Maquet Cardiovascular has acquired LAAx, the developer of an implantable left atrial appendage (LAA) closure device.
LAAx makes the TigerPaw System II, a mechanical occlusion device that is indicated for the occlusion of the LAA under direct visualization, in conjunction with other open cardiac surgical procedures. The device is approved in the U.S. and the European Union, according Rastatt, Germany-based Maquet.
The implanted TigerPaw System II uses a single-use delivery tool and an implantable fastener to occlude the LAA during open chest procedures. “We believe TigerPaw II will be a best-in-class device for reliable ligation of the LAA, potentially mitigating post-operative stroke and its associated costs in patients with atrial fibrillation undergoing cardiac surgery,” Peter Hinchliffe, president and CEO for the Cardiac Surgery Business Unit of Maquet, said in a release.
LAAx is based in Livermore, Calif. Terms of the acquisition were not disclosed.